By PPN News Staff
The FDA approved avelumab (Bavencio, EMD Serono/Pfizer) with axitinib (Inlyta, Pfizer) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
This is the first FDA approval for an anti–programmed death ligand-1 (PD-L1) therapy as part of a combination regimen for patients with advanced RCC. RCC is a type of cancer of which PD-L1 expression may contribute to inhibition of the immune response against the tumor. It is also a highly vascular